Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135711 | 0.90 | HRH3 (0.54) | SIGMAR1POLBL3MBTL3KCNJ1KCNH2 | |
| SCHEMBL998374 | 0.89 | SIGMAR1 (0.70) | SIGMAR1POLBL3MBTL3KCNH2KMT2A | |
| SCHEMBL2587783 | 0.82 | SLC6A3 (0.64) | SIGMAR1L3MBTL3SLC6A3HRH3MBTD1 | |
| SCHEMBL60705 | 0.81 | HRH3 (0.66) | KCNJ1KMT2AMEN1HRH3 | |
| SCHEMBL78043 | 0.81 | SIGMAR1 (0.79) | SIGMAR1POLBSLC6A3KMT2AHTR1A | |
| SCHEMBL9367020 | 0.81 | HRH3 (0.66) | SIGMAR1L3MBTL3SLC6A3HRH3MBTD1 | |
| SCHEMBL9539677 | 0.81 | SIGMAR1 (0.79) | SIGMAR1POLBSLC6A3KMT2AHTR1A | |
| SCHEMBL23637669 | 0.81 | SIGMAR1 (0.51) | SIGMAR1POLBL3MBTL3KCNH2SLC6A3 | |
| SCHEMBL3140579 | 0.80 | SIGMAR1 (0.62) | SIGMAR1POLBL3MBTL3KMT2AHTT | |
| SCHEMBL3141635 | 0.80 | SIGMAR1 (0.51) | SIGMAR1POLBL3MBTL3SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | claimed |
| EP-2387564-A1 | BENZO ÝC¨PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | Rutgers, The State University of New Jersey (US) | 2011-11-23 | — | — | EP | claimed |
| US-8037884-B2 | Modular system for patient positioning during medical procedures | ALLEN MEDICAL SYSTEMS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| WO-2010083436-A1 | BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-07-22 | — | — | WO | claimed |
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | claimed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | claimed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| EP-1765820-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-28 | — | — | EP | claimed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | claimed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| WO-2006002367-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-05 | — | — | WO | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| US-10065965-B2 | Imidazo[1,2-B][1,2,4]triazine derivatives as antiparasitic agents | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| CN-108368053-A | Substituted benzazepine derivatives as antibacterial compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20180141949-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | THE UNIVERSITY OF DUNDEE (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065965-B2 | Imidazo[1,2-B][1,2,4]triazine derivatives as antiparasitic agents | HDAC1, HDAC11, HDAC5 | SIGMAR1 1082/4885POLB 325/4885L3MBTL3 2467/4885 |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | SIGMAR1 3026/4885POLB 4152/4885L3MBTL3 4842/4885 |
| US-20180141949-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | HDAC1, HDAC11, HDAC5 | SIGMAR1 1082/4885POLB 325/4885L3MBTL3 2467/4885 |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | LCK, FRK, FYN | SIGMAR1 4510/4885POLB 4751/4885L3MBTL3 2001/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | SIGMAR1 860/4885POLB 4123/4885L3MBTL3 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.